New hope for HS sufferers: Long-Term drug shows promise
NCT ID NCT04876391
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 26 times
Summary
This study looked at the long-term safety and effectiveness of the drug spesolimab for adults with hidradenitis suppurativa (HS), a painful skin condition. Participants who had already completed a previous spesolimab trial received injections every two weeks for two years. The goal was to see if the drug remains safe and helps control HS symptoms over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Universitaria Pisana
Pisa, 56126, Italy
-
CLI Reims Bezannes
Bezannes, 51430, France
-
Cityclinic Medical and Psychological Clinic Matusiak Partnership
Wroclaw, 50-566, Poland
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Dawes Fretzin Clinical Research Group, LLC-Indianapolis-58713
Indianapolis, Indiana, 46250, United States
-
Dermatology Research Associates
Los Angeles, California, 90045, United States
-
Dr. S. K. Siddha Medicine Professional Corporation
Newmarket, Ontario, L3Y 5G8, Canada
-
Erasmus Medisch Centrum-ROTTERDAM-50697
Rotterdam, 3015 GD, Netherlands
-
HOP Edouard Herriot
Lyon, 69437, France
-
HOP Larrey
Toulouse, 31059, France
-
Haukeland Universitetssykehus
Bergen, N-5021, Norway
-
Holdsworth House Medical Practice
Sydney, New South Wales, 2010, Australia
-
Hospital La Princesa
Madrid, 28006, Spain
-
Hospital Santa Creu i Sant Pau
Barcelona, 08026, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Katholisches Klinikum Bochum gGmbH
Bochum, 44791, Germany
-
Mayo Clinic, Rochester
Rochester, Minnesota, 55905, United States
-
Non-Public Health Care Facility LABDERM
Ossy, 42624, Poland
-
Nordlandssykehuset HF, Bodø
Bodø, N-8092, Norway
-
Oslo Universitetssykehus HF, Rikshospitalet
Oslo, N-0372, Norway
-
Ospedali Riuniti di Ancona
Ancona, 60123, Italy
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
Städtisches Klinikum Dessau
Dessau, 06847, Germany
-
Unity Clinical Research
Oklahoma City, Oklahoma, 73118, United States
-
University Hospital Ostrava
Ostrava, 708 52, Czechia
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60596, Germany
Conditions
Explore the condition pages connected to this study.